Andrew Schutte - RepliCel Life CEO Pres
| REPCF Stock | USD 0 0 950.00% |
Insider
Andrew Schutte is CEO Pres of RepliCel Life Sciences
| Age | 33 |
| Phone | 604 248 8730 |
| Web | https://www.replicel.com |
RepliCel Life Management Efficiency
The company has return on total asset (ROA) of (1.651) % which means that it has lost $1.651 on every $100 spent on assets. This is way below average. RepliCel Life's management efficiency ratios could be used to measure how well RepliCel Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nicole LaBrosse | Halozyme Therapeutics | 41 | |
| Linda Fitzpatrick | Sutro Biopharma | 67 | |
| MSPH MD | ACADIA Pharmaceuticals | 67 | |
| Dr DVM | Ibio Inc | 54 | |
| James Kihara | ACADIA Pharmaceuticals | 43 | |
| Francis Conway | Larimar Therapeutics | N/A | |
| Nancy Ruiz | Larimar Therapeutics | N/A | |
| Nicki Vasquez | Sutro Biopharma | 61 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Kevin PharmD | Axsome Therapeutics | 46 | |
| Nick DeLong | Ibio Inc | N/A | |
| Peter BSc | Syndax Pharmaceuticals | 55 | |
| Philip Scalzo | Biomarin Pharmaceutical | N/A | |
| Seth MD | Tonix Pharmaceuticals Holding | 66 | |
| Piyush JD | Alnylam Pharmaceuticals | N/A | |
| Louise RodinoKlapac | Sarepta Therapeutics | 46 | |
| MBA MBA | Biomarin Pharmaceutical | 71 | |
| Ryan Brown | Sarepta Therapeutics | 46 | |
| Richard Heyman | Syndax Pharmaceuticals | 67 | |
| Christopher Bryant | Halozyme Therapeutics | 63 | |
| Cornelis Kruif | Merus BV | 59 | |
Management Performance
| Return On Asset | -1.65 |
RepliCel Life Sciences Leadership Team
Elected by the shareholders, the RepliCel Life's board of directors comprises two types of representatives: RepliCel Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RepliCel. The board's role is to monitor RepliCel Life's management team and ensure that shareholders' interests are well served. RepliCel Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RepliCel Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA CPA, Chief Officer | ||
| Kevin McElwee, Chief Scientific Officer | ||
| MSc PMP, Clinical Consultant | ||
| Ben Austring, Chief Mang | ||
| Andrew Schutte, CEO Pres | ||
| BEd LLB, Corp Director | ||
| Rolf MD, Chief Board |
RepliCel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is RepliCel Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.65 | |||
| Operating Margin | (4.19) % | |||
| Current Valuation | 3.42 M | |||
| Shares Outstanding | 54.36 M | |||
| Shares Owned By Insiders | 68.42 % | |||
| Price To Earning | (1.00) X | |||
| Price To Sales | 8.35 X | |||
| Revenue | 353.74 K | |||
| Gross Profit | 353.74 K | |||
| EBITDA | (4.07 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in RepliCel Pink Sheet
RepliCel Life financial ratios help investors to determine whether RepliCel Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RepliCel with respect to the benefits of owning RepliCel Life security.